Jazz Pharma FY2025 revenue $4.3B (+5% YoY); GAAP net loss $356M vs $560M income in 2024

Jazz Pharmaceuticals plc

2025-FY EPS reported -$5.84 revenue$4,267,586,000

Total revenues record $4.3B in FY2025 (+5% YoY); Q4 revenue $1.2B (+10% YoY).
GAAP net loss $356M ($5.84 diluted loss per share) vs prior year income of $560M ($8.65 EPS).
Non-GAAP adjusted net income $522M ($8.38 EPS) vs $1.35B ($20.65 EPS) in 2024; adjusted down significantly.
Xywav $1.7B (+12%), Epidiolex $1.1B (+9%) in 2025; Modeyso launch generated $48M.
2026 revenue guidance $4.25-$4.50B; sBLA submission for zanidatamab in GEA expected in 1Q26.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.